NCT06490328View on ClinicalTrials.gov

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

May 20, 2025

Study Completion Date

May 20, 2025

Conditions
Advanced Prostate Cancer
Interventions
DRUG

DKF-MA102

Administered twice at 12-week intervals

Trial Locations (1)

Unknown

RECRUITING

Ewha Womans University mokdong Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Dongkook Pharmaceutical Co., Ltd.

INDUSTRY

NCT06490328 - Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter